SOL-MDD-301

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

The purpose of this research study is to determine whether the study drug, Solriamfetol, is safe and effective for the treatment of Major Depressive Disorder (MDD). Solriamfetol, also called Sunosi®, is approved by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for people who have excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea (OSA).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 08 May 2024. Study ID: 855744

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).